Use of EF5 to Measure the Oxygen Level in Tumor Cells of Patients Undergoing Surgery or Biopsy for Newly Diagnosed Supratentorial Malignant Glioma

Stopped early · Not applicable

Conditions studied: Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Diffuse Astrocytoma, Adult Ependymoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Adult Myxopapillary Ependymoma, Adult Oligodendroglioma, Adult Pilocytic Astrocytoma, Adult Pineal Gland Astrocytoma, Adult Subependymoma

In brief

This clinical trial is using EF5 to measure the oxygen level in tumor cells of patients undergoing surgery or surgery biopsy for newly diagnosed supratentorial malignant glioma. Diagnostic procedures using the drug EF5 to measure the oxygen level in tumor cells may help in planning cancer treatment

Key facts

Study ID: NCT00430079
Run by: National Cancer Institute (NCI)
People needed: 48
Starts: 2001-07-01
Last updated by the study team: 2013-01-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Histologically confirmed and/or clinical and imaging evidence of a new brain mass that is likely to be a supratentorial malignant glioma
Clinical condition and physiologic status indicative of debulking surgery or biopsy as standard initial therapy
Performance status - Karnofsky performance status 60-100%
WBC greater than 2,000/mm\^3
Platelet count greater than 90,000/mm\^3
Creatinine less than 2.0 mg/dL
No significant cardiac condition that would preclude study therapy
No symptomatic congestive heart failure
No unstable angina pectoris
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception during and for 1 month after study completion
Weight no greater than 130 kilograms
No grade 3 or 4 peripheral neuropathy
No other invasive malignancy within the past 3 years that is likely to cause a solitary supratentorial metastasis
No uncontrolled concurrent illness, medical condition, psychiatric illness, or social situation that would preclude study participation
At least 6 months since prior chemotherapy
Concurrent corticosteroid therapy allowed
At least 6 months since prior radiotherapy to lesion or site of lesion
At least 6 months since prior surgery to lesion or site of lesion except incisional or core biopsy
Concurrent anticonvulsant therapy allowed
No other concurrent investigational agents

Where it is running

Abramson Cancer Center of The University of Pennsylvania — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.